Teva- Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.
Current Price
$35.73
-0.78%GoodMoat Value
$21.98
38.5% overvaluedTeva- Pharmaceutical Industries Ltd (TEVA) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Teva- Pharmaceutical Industries Ltd's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $17.35B. Gross profit (TTM) is $9.03B. EBITDA is $3.30B. Earnings per share (EPS) is $1.21. The P/E ratio is 26.27. Market capitalization is $41.08B.
Free cash flow (FCF) is $1.15B. FCF growth rate is 31.40%. EPS growth CAGR is 50.00%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Teva- Pharmaceutical Industries Ltd's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
